Hi Grenfire,
I missed your earlier post. No, I don't hold zero optimism.
It's really a balancing of the risk. There is a chance that there will be a significantly good result, it's just my analysis indicates that the balance of probability is that the result may be non significant with a trend which will be clinically insignificant. eg something like a benefit of 30 days which is not statistically insignificant. These comments relate to the can-003 study. That sort of result increases the risk on other clinical trials and the regulatory and partnering risk.
There may be other clinical trials which have hope, but it was this study which was providing near-term hope of a good result and increase in SP. A lot of investors bought in that hope. My view is that if there is good data to come, it is now further off than I previously thought with a higher risk factor.It may become a buy at some stage, but in my opinion. not yet.
- Forums
- ASX - By Stock
- interim data from can-003 clinical trial
IMM
immutep limited
Add to My Watchlist
2.00%
!
24.5¢

Hi Grenfire,I missed your earlier post. No, I don't hold zero...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $357.7M |
Open | High | Low | Value | Volume |
25.0¢ | 25.0¢ | 24.0¢ | $419.2K | 1.737M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 301706 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 28117 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 301706 | 0.240 |
6 | 305882 | 0.235 |
11 | 330086 | 0.230 |
13 | 511200 | 0.225 |
17 | 1170248 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.245 | 28117 | 2 |
0.250 | 161392 | 6 |
0.255 | 114804 | 6 |
0.260 | 268899 | 9 |
0.265 | 486184 | 4 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online